(Q33755990)

29 July 2017

Hepatitis C virus: an overview of current approaches and progress (English)

1 reference

29 July 2017

1 reference

1 reference

Walker MA

1

1 reference

29 July 2017

1 November 1999

1 reference

29 July 2017

1 reference

29 July 2017

4

1 reference

29 July 2017

11

1 reference

29 July 2017

518-529

1 reference

Hepatitis C virus: a historical perspective

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

1 reference

7 January 2021

Actions of cytokines on the immune response and viral interactions: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

The treatment of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

Molecular mechanisms of action of ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

The molecular virology of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

On the size of the active site in proteases. I. Papain

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

Hepatitis C virus NS3/4A protease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

Novel hepatitis C virus protease inhibitors: thiazolidine derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

Non-peptide inhibitors of HCV serine proteinase

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

Mechanistic role of an NS4A peptide cofactor with the truncated NS3 protease of hepatitis C virus: elucidation of the NS4A stimulatory effect via kinetic analysis and inhibitor mapping

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

Product inhibition of the hepatitis C virus NS3 protease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

Peptide-based inhibitors of the hepatitis C virus serine protease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

Affinity selection of a camelized V(H) domain antibody inhibitor of hepatitis C virus NS3 protease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

Characterization of engineered hepatitis C virus NS3 protease inhibitors affinity selected from human pancreatic secretory trypsin inhibitor and minibody repertoires

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

Design of selective eglin inhibitors of HCV NS3 proteinase

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

Selection of RNA aptamers that bind specifically to the NS3 protease of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

Isolation of RNA aptamers specific to the NS3 protein of hepatitis C virus from a pool of completely random RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

Prodrug strategies to enhance the intestinal absorption of peptides

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

Expression, isolation, and characterization of the hepatitis C virus ATPase/RNA helicase

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

C-terminal domain of the hepatitis C virus NS3 protein contains an RNA helicase activity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

Structure of the hepatitis C virus RNA helicase domain

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

cis-acting RNA elements required for replication of bovine viral diarrhea virus-hepatitis C virus 5' nontranslated region chimeras

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

Inhibition of hepatitis C virus replication by antisense oligonucleotide in culture cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

Phosphorothioate antisense oligodeoxynucleotides capable of inhibiting hepatitis C virus gene expression: in vitro translation assay

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

Core specific antisense phosphorothioate oligodeoxynucleotides as potent and specific inhibitors of hepatitis C viral translation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

Targeted inhibition of hepatitis C virus-directed gene expression in human hepatoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

A hitchhiker's guide to antisense and nonantisense biochemical pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

Intracellular cleavage of hepatitis C virus RNA and inhibition of viral protein translation by hammerhead ribozymes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

Identification of four conserved motifs among the RNA-dependent polymerase encoding elements

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

Complex formation of NS5B with NS3 and NS4A proteins of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

Expression, purification, and partial characterization of HCV RNA polymerase

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

Binding of hepatitis C virus to CD81

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901414-2

7 January 2021

10.1016/S1359-6446(99)01414-2

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10529769